Cargando…
Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548024/ https://www.ncbi.nlm.nih.gov/pubmed/36223679 http://dx.doi.org/10.1016/j.ejca.2022.09.006 |
| _version_ | 1784805364803305472 |
|---|---|
| author | Di Noia, Vincenzo Pimpinelli, Fulvia Renna, Davide Campo, Flaminia Cosimati, Antonella Torchia, Andrea Marcozzi, Benedetta Massacci, Alice Pallocca, Matteo Pellini, Raul Morrone, Aldo Cognetti, Francesco |
| author_facet | Di Noia, Vincenzo Pimpinelli, Fulvia Renna, Davide Campo, Flaminia Cosimati, Antonella Torchia, Andrea Marcozzi, Benedetta Massacci, Alice Pallocca, Matteo Pellini, Raul Morrone, Aldo Cognetti, Francesco |
| author_sort | Di Noia, Vincenzo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9548024 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95480242022-10-11 Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed? Di Noia, Vincenzo Pimpinelli, Fulvia Renna, Davide Campo, Flaminia Cosimati, Antonella Torchia, Andrea Marcozzi, Benedetta Massacci, Alice Pallocca, Matteo Pellini, Raul Morrone, Aldo Cognetti, Francesco Eur J Cancer Letter to the Editor Elsevier Ltd. 2022-11 2022-10-09 /pmc/articles/PMC9548024/ /pubmed/36223679 http://dx.doi.org/10.1016/j.ejca.2022.09.006 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Di Noia, Vincenzo Pimpinelli, Fulvia Renna, Davide Campo, Flaminia Cosimati, Antonella Torchia, Andrea Marcozzi, Benedetta Massacci, Alice Pallocca, Matteo Pellini, Raul Morrone, Aldo Cognetti, Francesco Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed? |
| title | Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed? |
| title_full | Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed? |
| title_fullStr | Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed? |
| title_full_unstemmed | Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed? |
| title_short | Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed? |
| title_sort | duration of humoral response to the third dose of bnt162b2 vaccine in patients with solid cancer: is fourth dose urgently needed? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548024/ https://www.ncbi.nlm.nih.gov/pubmed/36223679 http://dx.doi.org/10.1016/j.ejca.2022.09.006 |
| work_keys_str_mv | AT dinoiavincenzo durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT pimpinellifulvia durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT rennadavide durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT campoflaminia durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT cosimatiantonella durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT torchiaandrea durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT marcozzibenedetta durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT massaccialice durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT palloccamatteo durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT pelliniraul durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT morronealdo durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded AT cognettifrancesco durationofhumoralresponsetothethirddoseofbnt162b2vaccineinpatientswithsolidcancerisfourthdoseurgentlyneeded |